Medios AG announced today that it is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidating patient-specific manufacturing at its remaining locations across Germany. Production has already been relocated, and supplies to pharmacies and hospitals are guaranteed, according to a press release. The Aschaffenburg site most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation.
The decision comes as the business of patient-specific formulations faces sustained margin pressure, particularly due to price regulatory adjustments. Medios is countering this with measures to increase efficiency. In Germany, Medios operates a network of six GMP manufacturing facilities for patient-specific therapies. GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management. The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Continued economic operation was no longer feasible, and structural renovation work currently required at the site accelerated the implementation of this decision.
The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability. Thomas Meier, CEO of Medios AG, stated: “With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.”
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine. Medios AG is Germany's first listed specialty pharmaceutical company, and its shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index.
This optimization reflects broader industry trends where companies are consolidating operations to maintain profitability in the face of regulatory pressures. For more information about Medios AG, visit www.medios.group. The original press release is available at www.newmediawire.com.
